CAPETTI, AMEDEO FERDINANDO
CAPETTI, AMEDEO FERDINANDO
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients
2018 A. Ciccullo, G. Baldin, A. Capetti, S. Rusconi, G. Sterrantino, G. D'Ettorre, M. Colafigli, S. Modica, F. Lagi, A. Giacomelli, M.V. Cossu, S. Restelli, A. De Luca, S. Di Giambenedetto
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents
2019 V. Giacomet, M.V. Cossu, A.F. Capetti, G.V. Zuccotti, G. Rizzardini
Analyzing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicenter cohort of virologically-suppressed PLWHIV
2023 A. Ciccullo, G. Baldin, G. Sterrantino, M.V. Cossu, A. Giacomelli, F. Lagi, D. Farinacci, V. Iannone, R. Anna Passerotto, A.F. Capetti, S. Antinori, C. Mussini, V. Borghi, S. DI GIAMBENEDETTO
Antiretroviral therapy through barriers : a prominent role for nanotechnology in HIV-1 eradication from sanctuaries
2016 F. Corsi, L. Sorrentino, S. Mazzucchelli, M. Truffi, A. Capetti, G. Rizzardini, L. Fiandra
Brief Report : Impact of the COVID-19 Pandemic on Virological Suppression in People Living With HIV Attending a Large Italian HIV Clinic
2021 A. Giacomelli, C. Bonazzetti, F. Conti, L. Pezzati, L. Oreni, V. Micheli, A. Mancon, S. Vimercati, M. Albrecht, M. Passerini, M.V. Cossu, A.F. Capetti, P. Meraviglia, S. Antinori, G. Rizzardini, M. Galli, A.L. Ridolfo
Cohort profile : The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
2019 A. Ciccullo, G. Baldin, A. Capetti, V. Borghi, G. Sterrantino, A. Latini, G. Madeddu, L. Celani, F. Vignale, B. Rossetti, A. Dusina, M.V. Cossu, S. Restelli, W. Gennari, F. Lagi, A. Giacomelli, M. Colafigli, L. Brescini, A. Borghetti, C. Mussini, S. Rusconi, S. Di Giambenedetto
Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies : evidence from Phase I studies in healthy volunteers
2014 M.V. Cossu, D. Cattaneo, S. Fucile, P. Pellegrino, S. Baldelli, V. Cozzi, A. Capetti, E. Clementi
Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers : a randomized, open-label, 2-period, single-dose, crossover phase 1 study
2015 D. Cattaneo, M.V. Cossu, S. Fucile, A. Riva, S. Baldelli, P. Meraviglia, S. Landonio, C. Impagnatiello, C. Resnati, M. Galli, E. Clementi, A. Capetti, G. Rizzardini, C. Gervasoni
Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects
2022 F. Borgonovo, C.A. Stangalini, C. Tinelli, C. Mariani, D. Mileto, M.V. Cossu, L. Abbati, L. Bilardo, G. Gagliardi, M. Cutrera, M. Pellicciotta, L. Armiento, G. Dedivitiis, A.F. Capetti, G. Rizzardini
Dolutegravir plus rilpivirine as a switch option in cART-experienced patients : 96-week data
2018 A.F. Capetti, M.V. Cossu, G. Sterrantino, G. Barbarini, S. Di Giambenedetto, G.V. De Socio, G. Orofino, A. Di Biagio, B.M. Celesia, S. Rusconi, B. Argenteri, G. Rizzardini
Effects of ritonavir and cobicistat on dolutegravir exposure : when the booster can make the difference
2017 C. Gervasoni, A. Riva, V. Cozzi, A.F. Capetti, G. Rizzardini, E.G.I. Clementi, D. Cattaneo
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study
2019 G. Baldin, A. Ciccullo, A. Capetti, S. Rusconi, G. Sterrantino, M. Cossu, A. Giacomelli, F. Lagi, A. Latini, P. Bagella, A. De Luca, S. Di Giambenedetto, G. Madeddu
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients
2017 A. Borghetti, G. Baldin, A. Capetti, G. Sterrantino, S. Rusconi, A. Latini, A. Giacometti, G. Madeddu, C. Picarelli, R. De Marco, M.V. Cossu, F. Lagi, R. Cauda, A. De Luca, S. Di Giambenedetto
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016
2018 B. Rossetti, S. Di Giambenedetto, C. Torti, M.C. Postorino, G. Punzi, F. Saladini, W. Gennari, V. Borghi, L. Monno, A.R. Pignataro, E. Polilli, M. Colafigli, A. Poggi, S. Tini, M. Zazzi, A. De Luca, V. Mellace, A. Capetti, M.R. Gismondo, M.L. Biondi, C. Mussini, M. Pecorari, N. Gianotti, D. Sacchini, G. Parruti, F. Baldelli, S. Zanussi, A. Nerli, L. Lenzi, C. Calzetti, A. Vivarelli, R. Maserati, F. Baldanti, F. Poletti, V. Mondino, M. Malena, A. Cascio, G. Filice, G. Magnani, A. Zerbini, F. Lombardi, S. Di Gaimbenedetto, M. Andreoni, M. Montano, V. Vullo, O. Turriziani, A. Gonnelli, E. Boeri, S. Bonora, V. Ghisetti, D. Francisci, P. Grossi, P. Bagnarelli, L. Butini, R. del Gobbo, A. Giacometti, D. Tacconi, A. Callegaro, F. Maggiolo, A. Zoncada, E. Paolini, L. Sighinolfi, G. Colao, P. Corsi, P. Blanc, L. Galli, P. Meraviglia, A. Tosti, B. Bruzzone, M. Setti, G. Penco, A. Di Biagio, C. Nencioni, R. Pardelli, I. Arcidiacono, A. Degiuli, M. De Gennaro, A. Soria, A. Foc, S. Latella, L. Cosco, S. Malandrin, P. Milini, P. Cicconi, S. Rusconi, V. Micheli
Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders
2011 S. Piconi, S. Parisotto, G. Rizzardini, S. Passerini, R. Terzi, B. Argenteri, P. Meraviglia, A. Capetti, M. Biasin, D. Trabattoni, M. Clerici
Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study
2021 F. Borgonovo, M. Passerini, M. Piscaglia, V. Morena, A. Giacomelli, L. Oreni, G. Dedivitiis, A. Lupo, S. Falvella, M.V. Cossu, A.F. Capetti
Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients
2019 G. Baldin, A. Ciccullo, S. Rusconi, A. Capetti, G. Sterrantino, M. Colafigli, G. D'Ettorre, A. Giacometti, M.V. Cossu, A. Borghetti, W. Gennari, C. Mussini, V. Borghi, S. Di Giambenedetto
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial
2013 S. Rusconi, P. Vitiello, F. Adorni, E. Colella, E. Focà, A. Capetti, P. Meraviglia, C. Abeli, S. Bonora, M. D'Annunzio, A. Di Biagio, M. Di Pietro, L. Butini, G. Orofino, M. Colafigli, G. D'Ettorre, D. Francisci, G. Parruti, A. Soria, A.R. Buonomini, C. Tommasi, S. Mosti, F. Bai, S. Di Nardo Stuppino, M. Morosi, M. Montano, P. Tau, E. Merlini, G. Marchetti
Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art
2017 L. Fiandra, A. Capetti, L. Sorrentino, F. Corsi
OPERA : responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy
2015 R. Bruno, G. Cariti, P. Nasta, A. Capetti, V. Ravasio, M. Galli, E. Raise, G. Palmieri, C. Iannacone, M. Puoti